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Introduction 
Hepatitis C is a virus transmitted through contact with infected blood or blood products. 
Infection with the virus presents with few, if any, symptoms and individuals can have the virus 
for several decades before diagnosis. It is an insidious disease and the diagnosis often carries a 
social stigma. While the rate of new infections has been declining; the rate of chronic hepatitis C 
related liver disease has increased (CDC, 2007).  The role of primary care providers, particularly 
advanced practice nurses, in ordering appropriate tests for screening and management of patients 
infected with HCV is an important component of care and an understanding of the virus, and 
those at greatest risk, will aid in reducing potential complications of chronic HCV. This paper 
discusses the role of the primary care provider in diagnosis of HCV, counseling and education 
for patients and their families, and referral to a gastroenterologist or hepatologist for continuing 
care and possible treatment of HCV. The primary care provider is an important link, working in 
collaboration with medical specialists for effective management of those with HCV.   
Epidemiology & Public Health Disease Burden 
According to the Centers for Disease Control and Prevention (2008), the most common 
blood borne pathogen is hepatitis C; it is also the leading cause of chronic liver disease as well as 
the primary indication for liver transplantation. Approximately 4.1 million individuals in the 
United States, or 1.6% of the population, have antibodies for HCV (anti HCV), and it is 
estimated that 3.2 million people, 1.3% of the population have chronic HCV.  Currently, the peak 
prevalence of HCV is in the age group of 40 to 49 years, as compared with the findings of a 
similar survey in the 1990’s showing most of those infected were ages 30-39. (Ghany, M, G., 
Strader, D, B., Thomas, D, L., Seef, L, B., 2009). The increasing age of the population with HCV 
indicates that the majority of those infected were exposed during the 1960’s and 1970s, a period 
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of time of increasing experimentation with illicit drugs. The number of new cases of HCV has 
decreased from an estimated 230,000 new cases per year in the 1980’s to the current level of less 
than 30,000 new cases per year. The majority of new cases of HCV likely were contracted 
decades ago; however, have just come to clinical recognition when individuals seek care for 
other health reasons (AASSLD Guidelines, 2009).  Also, considering that chronic hepatitis C 
infection causes little or no symptoms and acute HCV infection is usually mild with vague flu 
like symptoms, the virus can remain undetected for many years or even decades. Those at 
greatest risk for acquiring the infection are IV drug users, individuals who had a blood 
transfusion before 1992, hemodialysis patients, and health care workers with an exposure from a 
needle stick injury, although this accounts for very few cases. The perinatal route of HCV 
transmission is rare; occurring only 5 % of the time (CDC 2007). Sexual transmission, carries an 
overall risk of 5%, is more common among men who have sex with men, those with a history of 
sexually transmitted infections and, multiple sexual partners. The transmission risk for those in a 
monogamous relationship is less than 1 % (Ghany, et al, 2009).  
The incidence of HCV may be under reported since many high risk groups were not 
included in the majority of HCV studies, such as individuals who are incarcerated, 
institutionalized or homeless (Flamm, 2007). To illustrate this point, a study from the Maryland 
Department of Corrections tested newly detained prisoners between January and March of 2002 
and found 29.75% were infected with HCV, while the rate of infection of HIV was 6.6% and 
Hepatitis B was 25.2% (Rustigi, V, K, 2006 [Solomon, L, Flynn, c, Muck, K, Vertefuille, J, 
2004]).  
HCV infection takes a toll on those infected, the public, as well as the healthcare system 
and is an ever-growing concern. Chronic HCV is the cause of approximately 10,000 to 12,000 
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deaths per year in the United States. The increase in the number of those infected with chronic 
HCV and the mortality of those who advance to cirrhosis and potentially hepatocellular 
carcinoma (HCC) is expected to increase significantly between 2010 and 2019 (McHutchinn, J. 
G, 2004).  Nonetheless the costs of caring for the long term liver damage resulting from chronic 
HCV infection can affect individuals, their families, friends and caregivers. There is a loss of 
productivity, loss of emotional support and increased sense of isolation. The strain on the health 
care system has increased and the burden of the disease will continue to increase moving into the 
next few decades (Taylor-Young, P, Hildebrandt, E, 2009).  
Pathophysiology 
 The primary functions of the liver include filtration of blood and creation of bile. The 
liver processes 25 % of the cardiac output of blood, equal to 1500 mL every minute. Blood flow 
to the liver is via the portal system, a dual blood supply. The hepatic artery brings blood to the 
liver, and the portal vein branches from the small bowel bringing nutrients, as well as pancreatic 
hormones into the liver (McPhee, S, J, Hammer, G, D, 2010).   
Humans are the only known natural vector for HCV infection (Pawlotsky, J, M, 2003).  
The hepatitis C virus is part of the Flavivirdae family of viruses; a single stranded RNA, genome 
hepacivirus (2010). Replication of HCV takes place in the hepatocytes. HCV is a spherical virus, 
approximately 50 nm in size (Mahy, B, W, J, Dictionary of Virology, 2005), and can also be 
found within several other areas of the body, such as peripheral blood cells, dendritic cells, 
epithelium and the central nervous system (O’Shea, R, S, Hepatitis C, 2010).   HCV has six 
genotypes theses are numbered 1-6, with as many as 50 subtypes (1a, 1b, 1c etc.). Genotype 1 is 
most prevalent in North America (70% of those infected); with the other genotypes more 
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prevalent in other parts of the world. Genotypes 1 and 4 are the most difficult to treat, requiring a 
longer course of treatment, while genotypes 2 and 3 typically have a greater chance of a 
sustained response after treatment. Because of the many quasi-species of HCV and the mutations 
the virus makes, it is able to elude immunological responses and persist in the body past the 
acute phase of the infection. These factors have left attempts to develop an effective vaccine with 
disappointing outcomes (McPhee & Hammer, 2010).  HCV causes acute infection which 
resolves on its own in 20-50 % of cases, but this does not constitute lifelong immunity to the 
virus. The transition to chronic infection occurs in the majority of cases, leading to cirrhosis and 
eventually the increased risk of hepatocellular carcinoma (HCC) (Pawlotsky, J, M., 2004). Injury 
to the liver from chronic HCV is mainly from an immunological response is thought to aid in the 
few cases of recovery from the acute infection. (Baptiste, A., Krahn, M., Heathcote, J., 
Tomlinson, G., 2009).  
The effects of hepatitis C are not limited to the liver (Table 1). HCV can affect multiple 
body systems including the hematologic, renal, dermatologic, endocrine, neurologic and immune 
system (Palekar, N, A., and Harrison, S, A., 2005). While some of these diseases are common to 
hepatitis C, such as mixed cryoglobinemia, most of these extrahepatic manifestations are 
uncommon. Knowledge of manifestations of hepatitis C outside of the liver can influence 
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Table 1 
Extrahepatic Manifestations of Hepatitis C 
Hematologic • Mixed cryoglobulinemia 
• B-cell non-Hodgkins Lymphoma 
Autoimmune • Lymphocytic sialadenitis 
• Autoantibodies 
• Idiopathic thrombocytopenic purpura 
Renal • Membranoproliferative glomerulonephritis 
• Membranous nephropathy 
• Fibrillary glomerulonephritis 
• Rapid progressive glomerulonephritis 
• IgA nephropathy 
Dermatologic • Porphyria cutanea tarda 
• Leukocytoclastic vasculitis 
• Lichen planus 
Neurologic • Peripheral neuropathy 
• Guillain-Barre syndrome  
Endocrine • Hypothyroidism 
• Diabetes mellitus 
                    Palekar, N, A., and Harrison, S, A., Extrahepatic Manifestations of Hepatitis C 
Screening 
The United States Preventative Services Task Force in 2006 did not find sufficient 
information that screening for HCV in high risk groups is able to impact the future of health care 
costs (USPSTF, 2006). In contrast the CDC recommends those at high risk be screened, and that 
this screening be facilitated in primary care, specialty care and public health settings. Education, 
counseling and opportunities for testing need to be made available for high risk populations. The 
AASLD guidelines for the Diagnosis, Management and Treatment of Hepatitis C: An Update 
(Ghany, M, G, Strader, D, B, Thomas, D, L, Seef, L, B, 2009) recommend those at highest risk 
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be educated, counseled and tested for HCV.  Screening should  occur  (1) “as part of a 
comprehensive health evaluation, all persons should be screened for behaviors that place them at 
high risk for HCV infection” and (2) “Persons who are at high risk should be tested for the 
presence of HCV infection” (Ghany et al, 2009). Studies which would aid primary care providers 
in the diagnosis of HCV include those examining the effectiveness of screening, the use of a 
screening tool in order to identify those at highest risk, specific testing criteria, and an algorithm 
for appropriate laboratory testing.  The detection of HCV at an earlier stage could reduce the 
risks and disease burden.   
Literature Review 
Screening Tools 
Nguyen, Herrine, Laine, Ruth and Weinberg (2005) developed a screening tool to assess 
patients at risk for exposure to HCV; the cross-sectional study examined a patient administered 
questionnaire, looking at seven factors that are strongly associated with HCV exposure. The 
seven question survey was focused from the results of a 72 question tool, self-administered by 
the 220 study participants. Examples of risk behaviors are having sex with a prostitute, injection 
drug use, a blood transfusion before 1992, witnessing illicit drug use and refusal as a blood donor 
or life insurance applicant.  
Participants were randomly selected from the gastroenterology division clinic and an 
internal medicine clinic in a large teaching hospital. The first group of participants was known to 
have HCV antibodies, these patients were mainly from the gastroenterology division, the second 
group of patients from the general medicine division had not been tested for HCV, and did not 
have active liver disease. Inclusion requirements comprised of being 18-60 years old, able to 
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give informed consent and competency in written English. Participants were given a confidential 
identification number at the start of the study. General medicine patients tested for anti HCV 
antibody with positive results were counseled. Results of the questionnaire revealed there were 
strong correlations between positive HCV status and a history of sex with a prostitute, exposure 
to blood products and intravenous drug use. The highest correlation occurred with four or more 
risk factors for HCV present. 
Study limitations are related to the lack of diversity since participants had to be able to 
read and communicate in English. This would exclude those who had English as a second 
language. The study does not address individuals with limited or no access to healthcare, the 
homeless, undocumented workers and those who have been incarcerated.  
The use of a screening tool evaluated by McGinn, O’Connor-Moore, Alfandre, Gardenier 
& Wisnivesky (2008), using a Multivariable Logistic regression analysis, identified the 
probability of HCV antibody risk factors. A total of 1,000 participants were randomly selected 
from a primary care clinic, affiliated with a large academic center and hospital, located in East 
Harlem, New York. Participants from the clinic were mostly African American, Hispanic and 
those from a low socioeconomic situation. The exclusion criteria for the study were spoken 
language other than English or Spanish and age less than 18 years. The questionnaire was 
developed by the Jefferson Medical Center and consisted of 27 questions evaluating HCV risk 
factors in 5 domains including work, medical, exposure, personal care, and social history. After 
completing the questionnaire participants underwent HCV antibody testing. 83 of the participants 
had positive HCV antibodies (8.3%; 95% CI).  Of the positive results, mostly males and insured 
by Medicaid, 58 were known to have HCV antibodies, while 25 were newly diagnosed.  There 
were no differences among participants in race/ethnicity, education level or reason for seeking 
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care. A simplified questionnaire addressing three of the five domains, work, medical and social 
history was tested, which also showed a 95% CI. 
The limitations of the study included an inner city clinic population which may not be 
generalizable. The HCV positive participant questionnaires may show a bias and the tool should 
be validated within other population groups. The study concluded that the use of a tool for 
assessing risk factors for HCV infection is of value in the primary care setting, by targeting those 
at greatest risk screening can increase detection in a more cost-effective manner. 
The Department of Veterans Affairs in New York; conducted the screening of 5400 
veterans, using a questionnaire in the primary care clinics (Zuniga, J, J. Lane, D, S. In a study by 
Allmer, J. Jimenez-Lucho, V, E., Analysis of Hepatitis C Screening Programme for US veterans. 
2005). Using the guidelines from the Nutrition Health and Nutrition Examination Survey 
(NHANES III) the VA initiated HCV screening focusing on 11 potential risk factors, screening 
was recommended if the patient had 1 of 11 risk factors. The risk factors included (1) Viet Nam 
era service; (2) transfusion of blood before 1992; (3) IV drug use [past or present]; (4) blood 
exposure in or through the skin or mucus membranes; (5) multiple sex partners [past or present]; 
(6) hemodialysis; (7) tattoo or repeated body piercings; (8) intranasal use of cocaine [past or 
present]; (9) unexplained liver disease; (10) having been told of abnormal liver function tests; 
(11) intemperate ETOH [> 7 alcoholic beverages in per week] (2005). Lab testing included anti 
HCV ELISA, with confirmatory HCV PCR (polymerase chain reaction). Demographic data were 
obtained using the institution EMR and paper records. Data were reported using frequencies and 
percentages. The study found that of the 11 identified risk factors only five were found to be 
significant in predicting risk for HCV infection, these included (1) IV drug use; (2) Viet Nam 
Era veteran; (3) tattooing and body piercing; (4) Intemperate ETOH use; (5) blood transfusion 
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before 1992. The findings of the study indicated that a modified questionnaire could be used as a 
cost effective measure for screening and testing those at risk for HCV.  Study limitations 
included possible selection bias as more than half of veterans at this facility were not tested for 
HCV. The use of a questionnaire can contribute to recall bias on the part of the participants, 
although multivariate testing did not show a difference in this retrospective study. A cost 
analysis could identify if the use of five risk factor screening questionnaire could be effective in 
predicting HCV infection in those at risk. 
A more recent study completed by the U. S. Veteran Affairs, used the medical record of 
patients already identified to have tested positive for HCV and looked at the risk factor 
assessment of these patients (Mallette, C, Flynn, M, A, Promat, K, Outcome of Screening for 
Hepatitis C Virus Infection Based on Risk Factors, 2008). Participants included patients found to 
be HCV positive who were diagnosed through the VA mandatory HCV screening program from 
October 1, 1998 to May 11, 2004. Inclusion in the study required an assessment that included an 
interview identifying their risk factors for HCV, length of infection, current health and mental 
health conditions, history of ongoing and past ETOH use, and score utilizing the AUDIT-C 
screening tool. A physical examination, confirmatory HCV testing, liver function test, liver 
biopsy and abdominal ultrasound to screen for hepatoma were offered. Counseling regarding 
hepatitis C was provided as well as vaccination for hepatitis B and hepatitis A.  A review of 
medical records of 25,701 VA patients was examined, of those, 17,230 denied risk factors and 
were not offered testing for HCV antibodies. There were 8,471 participants who reported 1 risk 
factor, (5,646 had HCV testing), with 412 testing positive for infection and 228 having chronic 
HCV.  A total of 152 patients were excluded because their diagnosis was not made in connection 
with the mandatory screening program. A sub-group of 260 patients were diagnosed with HCV 
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solely through the VA screening, and were included for evaluation. Another 112 patients 
responded according to the protocol and had a full physical assessment; the remaining 148 
participants could not be reached, or declined to be involved in the study.  
Most of the participants (~88.4%) were able to confirm at least 1 risk factor, (70.5 % had 
injection drug use or blood transfusion before 1992 as their risk factor), 21.5% had more than 1 
risk factor and 13.4 % did not report traditional risk factors. Confirmatory testing, HCV RNA 
PCR or RIBA, showed that of 219 patients, 38 of these had a false-positive HCV antibody test. 
Of the 211 who had HCV RNA PCR testing 122 were shown to have chronic HCV infection. 
The positivity of the anti-HCV testing showed 7.3% (95% CI 6.6-8.0%), this is higher than 
previously thought. The result of the study concluded that screening for risk factors for HCV had 
value. Findings also suggested the importance of confirmation with a test such as HCV RNA 
PCR with reflex testing of positive samples for confirmatory lab studies given that many of the 
participants did not return for follow-up testing after preliminary evaluation.   
Management of HCV in the Primary Care Setting 
Primary care providers are poised to be a force in the diagnosis and management of 
patients with chronic HCV infection. Screening of patients for tobacco, alcohol and drug use 
could be expanded to include risk factors for HCV, as these risk factors are also associated with 
other viruses such as HIV and HBV. The knowledge needed in order to approach testing and 
management of these patients can be daunting for PCPs who are expected to manage many more 
patients with complicated comorbid health problems. Even though the rate of new infection with 
HCV has dropped, the rate of new diagnosis of chronic HCV continues to rise.  
11 
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The patient with chronic HCV infection requires a referral to a gastroenterologist or 
hepatologist for possible treatment and continued management, screening for HCC, fibrosis, and 
cirrhosis. Treatment of the patient infected with HCV is a long and arduous process; this is best 
managed by a specialist. The treatment regimen requires a provider to have expertise in the 
management, as well as potential side effects and complications of treatment.  
There are few studies regarding primary care providers and HCV. With the increasing 
need for primary care providers and the declining numbers of physicians pursuing primary care, 
the role of APN’s in primary care is increasing. The primary care provider’s knowledge of 
epidemiology, pathophysiology, diagnosis and management of HCV is fundamental to their 
ability to assess patients for risk factors for HCV and screen appropriately. 
The management of chronic hepatitis C often falls to primary care providers; 
unfortunately, the treatment of hepatitis C is complicated and requires specialized knowledge of 
the medication regimen, side effects, and frequent monitoring patients require during this time. 
According to Zevin (2007) the treatment of hepatitis C must be more broadly defined. 
Consideration of primary providers as a logical source of care for people living with hepatitis C 
is a model which would increase access to care and funding in order to provide necessary 
treatment.  
Nurse Practitioners Role in the Diagnosis and Management of HCV 
Nurse practitioners in the primary care setting are a logical choice for the care of patients 
diagnosed with chronic hepatitis C. The holistic approach of nurse practitioners, based on 
theories of caring and patient autonomy is well suited to the care of HCV patients. This is a 
challenging group of patients. They are often motivated for treatment but either lack insurance or 
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government aid or are not able to start treatment due to ongoing drug and alcohol use. Even if 
patients do meet the criteria for treatment, the regimen is lengthy (~48 weeks), and medications 
have multiple side effects such as depression, anemia, flu like symptoms, and hair loss. Often 
these patients lack a support system and the NP is the “cheerleader” for the patient. The NP and 
clinic staff provides close medical supervision and emotional support, especially when treatment 
is affecting their lives in many adverse ways. 
As primary care providers, NP’s can screen and assess for complications of chronic HCV 
infection.  If the patient has been referred to specialty care, the primary care NP can continue 
monitoring the patient for signs of cirrhosis, decompensating cirrhosis and assist in their care 
during treatment. NPs work in gastroenterology and hepatology clinic settings treating HCV 
patients, and often times the majority of their care during treatment is provided by an NP. This 
provides the benefit of continuity of care that these patients may lack. There are few studies that 
look directly at the NP role in the care of the patient with Chronic Hepatitis C, but with the 
growing shortage of primary care providers in the face of health care reform, NPs are poised to 
become the main provider of care for those with HCV as well as other complex patients. 
An Australian study showed that the introduction of hepatology nurse practitioners 
(HNP) improved access and allowed more patients to be treated for HCV (Nazareth, S, Piercey, 
C, Tibbett, P, Cheng, W, Innovative practice in the Management of Chronic Hepatitis C: 
Introducing the Nurse Practitioner Model, 2005). The article addressed the need for greater 
access for individuals with HCV to receive treatment and management. The HNP role was 
created after approval had been gained and training was coordinated with the Nurses Board of 
Western Australia (NBWA). The HNP was able to prescribe medications, provide advanced 
assessment, initiate routine laboratory and imaging studies and refer to members of the 
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interdisciplinary teams. The role of the HNP included combined management utilizing drug 
treatment and coordination of the multiple psychosocial components of the patients care in order 
to achieve the best outcome while maintaining cost effectiveness. Working with the established 
clinic protocols and collaboration with the care team the HNP was able to provide care and 
treatment options for those who would not have had access to this specialized care. The patient 
satisfaction scores for the HNP reached more than 98%, while increasing the number of patients 
treated for hepatitis C from an average of 60 to 120 per year. This was a small study conducted at 
only one facility looking at the outcomes for an HNP as a new role, specifically designed for one 
practice, thus more study would need to be done for generalizability. The overall role of the 
Advanced Practice nurse is likely different in Australia than it is in the United States, and may 
not fully reflect the more autonomous role of NPs in the United States.   
The role of the advanced practice nurse in the treatment of HCV can be validated by 
other articles which are not necessarily research related, but do reflect the role NPs play in 
creating greater access for this group of patients. Clark and Ghalib, (1999) propose that the role 
of the NP, in caring for and educating patients regarding the risk factors, modes of transmission, 
disease course, and treatment options, to be critical in the future. The flexibility of the NP to be a 
PCP or to specialize in one area of care lends itself to the diagnosis and treatment of patients 
with HCV. In the primary care setting, NPs provide screening, surveillance and education. In the 
specialty area, NPs can co-manage the treatment of patients with anti-viral treatments in 
collaboration with a gastroenterologist or Hepatologist. Management of the treatment regimen 
and the control of side effects of treatment lend itself to the NP’s practice. The need for careful 
management of these patients is crucial for treatment completion. For example, by keeping side 
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effect journals and scheduling frequent follow-up for lab results and adjustment of medication 
dosages, NPs can greatly influence the outcomes of treatment for those infected with HCV.  
Patient and Family Counseling and Education 
Patients diagnosed with HCV as well as their families, should be counseled regarding the 
prevention of transmission to others and treatment of HCV. Those infected with HCV may have 
many questions regarding transmission, and may be embarrassed with a diagnosis of HCV as it 
can be as stigmatizing as HIV. Family members, significant others and friends along with the 
primary care provider can be a resource and support system for the patient with HCV.  
 The approach to counseling patients, families or caregivers regarding HCV is important 
in the treatment and establishing a trusting relationship with the patient. A recent study from 
Australia showed that approaching patients and assessing their strengths and providing pre-
treatment assessment and counseling can help improve patient compliance with treatment and 
overall healthy behaviors (Hopwood, M, Treloar, C, 2007).  
Patient and family education should be accurate and reassuring. The information should 
include disease management, modes of transmission as well as strategies for improving general 
health (Kerbelski, M, 2005). Mental health, as well as chemical dependency issues need to be 
addressed. HCV support groups, chemical dependency and mental health groups should also be 
encouraged. The education of HCV patients has often fallen to physicians, but patient education 
is more often a part of nursing and the education of these patients might be better suited to the 
advanced practice nurse (Kerbelski, 2005).   
Maintaining or improving health should be a priority for HCV patients in order to 
decrease the progression of liver damage. One of the most crucial areas that improves health and 
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slows the progression of liver damage and worsening of fibrosis is abstinence from alcohol. 
There is some debate as to whether complete abstinence or the “light” use of alcohol for health 
benefits is most beneficial. In a study looking at the question of a “safe” level of alcohol 
consumption, this was not shown to be the case. Alcohol intake at all levels contributes to 
progression of liver fibrosis (Monto, A, Patel, K, Pianko, S, Pockros, P, McHutchison, J, G. 
Wright, T, L, 2004). It is thought that even three drinks per day can enhance replication of HCV. 
The intake of alcohol can stress the cells of the liver and lead to increased scarring (fibrosis) of 
the liver and speed the progression to cirrhosis (Monto, A, 2002).   
In managing patients with HCV, daily exercise can be beneficial both physically and 
emotionally. Patients often have symptoms of fatigue, depression and insomnia. Daily exercise 
has been shown to have multiple health benefits for the general population, as well as for patients 
with HCV. For instance patients with lower body weight have a greater chance of completing 
combination treatment with fewer adverse side effects (Levine, C, D., Ghalib, R, H., 
2005).Exercise has also been shown to decrease stress and improve mood along with 
contributing to better sleep patterns. Regular exercise helps to prevent complications from 
diabetes and cardiovascular disease, obesity contributes to fatty liver disease. There are few 
studies of the benefit of exercise and hepatitis C, but further research could be done in this area. 
The positive effects of exercise for the general population can easily be applied to those with 
HCV (McKenna, O, Blake, C, 2007).  
Mental health issues are common among patients with hepatitis C. Making sure that 
psychiatric concerns are under control and that the patient has a good support system in place 
prior to treatment to aid in management of side effects or for continued abstinence form illicit 
drugs and ETOH will improve outcomes. Many times the family and friends of the patient, due 
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to past behavior of the individual with HCV, are not supportive or involved and ultimately the 
patient needs to develop a support system. Depression is a major side effect of treatment for 
HCV, adequate control of depression is required before treatment can be continued (Brennan, C, 
S., 2010).  
Immunity to HAV and HBV is recommended for patients with chronic HCV and 
vaccination should be offered. A study showed that out of 86,000 patients, who tested positive 
for HCV, 82.2% were tested for HBV and 68.6% were tested for HAV.  Of the patients who 
were tested, 57.2% and 63.8% had no immunity to HBV and HAV respectively. Most of the 
patients who had been vaccinated for HBV and HAV had been seen by a provider specializing in 
HCV. Vaccination against HAV and HBV are now considered quality marker for the care of 
HCV patients (Kramer, J, R, Hachem, C, Y, Kanwal, F, Mei, M & El-Serag, H, 2010).  Table 2 
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Table 2 
Patient Counseling and Education Interventions 
Nutrition • Consume a healthy diet (plenty of fruits 
and vegetables. 
• Decrease the salt and sugar in your diet. 
• Decrease fats in the diet. 
Physical Activity • Regular exercise can help with weight 
loss. 
• Regular exercise can also help with 
decreasing depression. 
• Conserve energy when you can  
Treatment of Psychiatric Illness • Find ways to relax. 
• Make sure you get enough rest. 
• Reduce stress and anxiety. 
• If you have feelings of anxiety or 
depression contact your health care 
provider. 
• If you have an established relationship 
with a psychiatrist or counselor, see 
them on a regular basis.   
Abstaining from Alcohol • Alcohol can increase fibrosis 
• Causes further liver damage 
• Can cause faster progression of 
cirrhosis 
Smoking Cessation • General good health 
Supplements  • Be sure to inform your health care 
provider of any OTC medications and 
supplements you are taking. 
• Tylenol is hepatotoxic, and should be 
avoided. 
• NSAID (Advil, ibuprofen, Naprosyn, 
aspirin) 
• Vitamins especially those with iron 
should be avoided.  
Vaccinations • If no Immunity to Hepatitis B or 
Hepatitis A, the patient should have 
these vaccine series. 
• This is a quality measure for the care of 
patients with chronic hepatitis C or 
cirrhosis.  
Brennan, C., 2010 
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   Hepatitis C infection is a growing health concern. Having a screening tool available in 
the primary care setting would be influential in identifying those at risk for the infection, and has 
been proven to be instrumental in diagnosing those patients infected with the virus. The long-
term management and care for those with undiagnosed HCV infection can be costly in terms of 
morbidity and mortality of the patient as well as a strain on the healthcare system. The fact that 
chronic HCV infection is increasing, despite a decrease in new infections, shows the disease 
burden of HCV will continue to be problematic. Primary care providers particularly NPs have a 
major role to play in the screening and diagnosis of patients with HCV. 
 The care of the HCV may require referral to a physician or NP specializing in 
hepatology. This will require collaboration between the primary care provider and the specialist. 
The unique skills of the NP lend themselves to the care of these complex patients. The 
counseling and education and on-going treatment of the HCV patient, requires time and attention 
and a team effort by the providers and the staff, offering the patients support and encouragement 
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Websites 
www.cdc.gov. This website has a lot of information, statistics, and patient information. Most of 
the information is aimed at Health Care Providers. The website is difficult to navigate. 
www.aasld.com. The AASLD website has information regarding HCV and also addresses any 
liver disease. This website has the most up to date information for health care professionals and 
has some patient information. Research articles are available, updated guidelines for the 
treatment of HCV. 
www.mayo.com. The Mayo Clinic website is user friendly, particularly for patients and their 
families as well as for health care providers. The information is easy to understand and accurate. 
www.health.state.mn.us/divs/idepc/diseases/hepc/disease.html. The Minnesota Department of 
Health website is useful for providers and families, the site has information about HCV, support 
groups, testing and syringe services. It provides the provider with access to patient educational 
material in several languages. The site is difficult to navigate.  
www.hepatitis.va.gov. The VA website is very useful for providers. The site also has patient 
information and educational material it addresses coping with hepatitis c, transmission of the 
disease, diagnosis, treatment and management, healthy living options to help slow the 
progression of the disease and to better care for their liver. The site has research data and care 
management for the health care provider.  
http://www.liverfoundation.org/. The American Liver Foundation website has information 
geared towards patients as well as healthcare providers. It is easy to navigate and user friendly. 
They have information about liver diseases, fund raising events and clinical research trials.  
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